Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
PR Newswire•28/10/2026•16:05 ET
0
Key Highlights
- ➤$960 million quarter-end cash, cash equivalents and short-term investments
- ➤SUNRISE Phase 3 trials initiated for oral VK2735 in obesity
- ➤VK2735 maintenance study retained 82%-97% of weight loss with less-frequent dosing
- ➤VANQUISH Phase 3 trials expected to complete in 2027
- ➤VK3019 Phase 1 SAD study nearing completion; MAD study planned for 1Q27
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update PR Newswire
-- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance --
Get started
Create a free account to read the full story.